Comparison of an 18F labeled deravative of vasoactive intestinal peptide and 2-deoxy-2-[18F)fluoro-D-glucose in nude mice bearing breast cancer xenografts

Elaine M. Jagoda, Luigi Aloj, Jurgen Seidel, Lixin Lang, Terry W. Moody, Shielah Green, Corradina Caraco, Margaret Daube-Witherspoon, Michael V. Green, Willian C. Eckelman

Research output: Contribution to journalArticle


Purpose: A 18fluorine-labeled derivative of vasoactive intestinal peptide [18F- Arg15, Arg21 VIP(18F-dVIP)] was evaluated as a potential imaging agent for breast cancer by comparison with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) using standard ex vivo determinations and small animal position emission tomography (PET) imaging. Procedures: Human breast carcinomas, T-47D and MDA-MB231, tumor-bearing nude mice were injected intravenously with 18F-dVIP or FDG for imaging and/or biodistribution (ex vivo) determined by gamma counting. Results: FDG had two- to three-fold greater tumor accumulation and target-to-non target contrast relative to 18F-dVIP. VIP receptors were detected in both tumor types but in low concentrations (18 F-dVIP cleared into the kidneys. Conclusions: 18F-dVIP uptake in mice T-47D tumors and kidneys determined by imaging correlated with values determined by ex vivo counting suggesting that tumor and other tissue uptakes can be quantified by in vivo positron projection imaging.

Original languageEnglish
Pages (from-to)369-379
Number of pages11
JournalMolecular Imaging and Biology
Issue number5
Publication statusPublished - Sep 2002



  • F-dVIP and FDG in tumor mice
  • H-deoxyglucose
  • Biodistribution studies
  • Breast carcinoma
  • FDG
  • PET imaging of xenograft tumors
  • PET radiopharmaceuticals
  • Receptors
  • T-47D and MDA-MB231 human breast carcinomas in nude mice
  • Tumor mouse models of human breast cancer
  • Vosoactive intestinal peptide (VIP)

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this